Introduction
============

Obesity is a strong risk factor for the development of type II diabetes mellitus, cardiovascular diseases, and associated metabolic syndrome [@B1]. An emerging view is that adipose tissue distribution in various locations of the body affects the development and progression of metabolic diseases more than total fat mass [@B2]. Adipose tissues from different areas of the body display distinct structural and biochemical properties and have disparate roles in pathology. It is well known that visceral adipose tissues (VATs), which are localized within the abdominal and thoracic cavities, have been shown to be correlated with an increased risk of insulin resistance and cardiovascular diseases [@B3], [@B4], whereas increase of subcutaneous adipose tissues (SATs) are associated with favorable plasma lipid profiles [@B5]-[@B7].

Recently, there has been a greater appreciation for the roles of DNA methylation markers, which can be very dynamic and alter gene expression in response to environmental and developmental cues without changing DNA sequences, in the development of obesity [@B8], [@B9]. Feinberg *et al.* (2010) identified four variably methylated regions correlated with body mass index and were located in or near genes previously implicated in the regulation of body weight or diabetes [@B10]. Wang *et al*. (2010) provided evidence that obesity is associated with genome-wide DNA methylation changes in peripheral blood leukocytes [@B11].

Pig models are ideal for studying human obesity, as they have many similarities in structure and function to humans, including size, digestive physiology, adipose distribution, and dietary habits [@B12], [@B13]. Of equal importance, the epigenetic understanding of pig adipose deposition will improve economic benefits in the pig industry.

To investigate the systematic association between DNA methylation and adipose deposition, we used a clustering method to identify sets of functionally co-methylated genes linked to obesity-related phenotypes based on the comprehensive genome-wide methylation data from eight adipose tissues from different body sites used in Li *et al.*[@B14].

Materials and Methods
=====================

Animals and tissue collection
-----------------------------

Three females and three males at 210-day-old for each of the Landrace (a leaner, Western breed), the Tibetan (a feral, Chinese breed) and the Rongchang (a fatty, Chinese breed) pig breeds were used in this study. These pigs lived in comparable environments, but displayed distinct fat levels. The eight adipose tissues deposited in different body sites of each pig were sampled and divided into four groups: (1) three SATs (i.e. abdominal subcutaneous adipose (ASA), inner layer of backfat (ILB), and upper layer of backfat (ULB)); (2) three VATs from the abdominal cavity (i.e. greater omentum (GOM), mesenteric adipose (MAD), and retroperitoneal adipose (RAD)); (3) one VAT from the thoracic cavity (i.e. pericardial adipose (PAD)); and (4) intermuscular adipose (IAD). For detailed information regarding the animals and samples, please refer to Li *et al.*[@B14].

Measurements of obesity-related phenotype
-----------------------------------------

The representative obesity-related phenotypes of 18 individuals were determined. The body density of each pig was calculated, as previously described [@B15]. The pig body is considered to be like a truncated cone where the base is represented by the abdomen (A), the top by the neck (N) and the length by the body size (BS). Pig body volume was defined (l) as:
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where BS is the body size and A and N are the radius of the abdomen (A) and the neck (N).

It was then possible to determine the density in kg per litter as:
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Serum concentrations of total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), very-low density lipoprotein (VLDL), lactate dehydrogenase (LDH), apolipoprotein A-1 (Apo-A1) and apolipoprotein B (Apo-B) were determined in triplicates for each pig by using CL-8000 clinical chemical analyzer (Shimadzu, Tokyo, Japan). Serum levels of 16 cytokines, which are well known to be associated with adipose deposition, were measured in triplicates for each pig using a pig-specific ELISA kit (RuiCong, Shanghai, China). These analyzed molecules included adiponectin (Adipo), adiponectin receptor (AdipoR), C-peptide, cholecystokinin (CCK), gastrin receptor (GsaR), growth hormone (GH), highly sensitive C-reactive protein (hs-CRP), insulin, interleukin - 6 (IL-6), leptin (Lep), leptin receptor (LepR), orexin-B (OX-B), orexin receptor (OXR), plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-α (TNF-α) and somatostatin (SS).

Adipocyte volume was measured in each of 144 adipose samples, as previously described [@B16]. All adipose tissues were embedded in paraffin, sliced at a thickness of 6 μm and stained with hematoxylin and eosin. The mean diameter of an adipocyte cell was calculated as the geometric average of the maximum and minimum diameter, and 100 cells were measured for each sample in randomly selected fields. The mean adipocyte volume (*V*) was obtained according to the following formula:
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where *D~i~* is the mean diameter; *f~i~*denotes number of celles with that mean diameter *D~i~*.

Fatty acid composition was determined in each of 144 adipose samples using GC-14C gas chromatograph (Shimadzu), as previously described [@B17]. The fatty acid methyl esters were quantified and identified by comparison with standards previously run independently or together with samples. For more information, please refer to Li *et al.*[@B14].

Methylated DNA immunoprecipitation sequencing
---------------------------------------------

In total, 144 adipose samples were used for the construction of methylated DNA immunoprecipitation (MeDIP) libraries, as we previously described [@B18], and sequenced separately using Illumina HiSeq 2000 sequencing system, which generated ∼1,125 Gb of sequence data. All MeDIP-seq data were deposited into the NCBI\'s Gene Expression Omnibus database under the GEO Series accession number GSE30344. We referred to the UCSC pig reference genome (Sscrofa9.2) annotation data for the identification of differentially methylated regions (DMRs) in 17,930 promoters (-2,200 to +500 bp) across eight variant adipose tissues using our newly developed methodology by calculating the variation of a single CpG site. For more details, please refer to Li *et al.*[@B14].

Identification of co-methylated gene sets linked with obesity-related phenotypes
--------------------------------------------------------------------------------

In order to identify sets of functionally related genes with DMRs in their promoters that are linked to the phenotypic traits, we used a clustering method, as previously described [@B19], albeit with some modifications. Spearman rank correlation coefficients were determined between all possible gene-pairs across 18 individuals for each type of adipose tissue. The strongest correlated gene-pair was selected, and grouped together in a set that was assigned the average methylation value of the two genes that constituted the set. After the addition of this newly created set to the dataset, the two individual genes were removed from the data and the strongest correlation in the dataset was again selected. This resulted in either the expansion of a set already created or in the creation of a new set. We kept repeating this as an iterative process until the most significantly correlated pair had an *r*\< 0.80. Only the sets containing 100 or more genes were kept for further analysis. The co-methylated gene sets that reflected the average methylation value of the genes constituting that set were correlated with each of 29 obesity phenotypic traits using a non-parametric Spearman rank correlation coefficient with Bonferroni correction.

Results and Discussion
======================

Co-methylated gene sets linked with obesity-related phenotypes
--------------------------------------------------------------

As shown in Fig. [1](#F1){ref-type="fig"}, in a total of eight adipose tissues, we identified 44 co-methylated gene sets containing 100 or more genes with DMRs in their promoters. These gene sets comprised different number of genes across different adipose tissues. For example, in ILB, 3,268 genes could be grouped into eight gene sets, whereas in GOM, 2,511 genes could be only grouped into three gene sets. Co-methylated genes within a single gene set are strongly correlated whereas genes that belong to different gene sets generally do not show strong co-methylation.

The gene sets of each adipose tissue were analyzed for correlation with various obesity-related phenotypic traits of 18 pigs. Seven, eight, and three gene sets of SATs, VATs and IAD were significantly associated with a trait after Bonferroni correction for multiple testing (*P*\< 0.001), respectively (Fig. [2](#F2){ref-type="fig"}). To further define the biological mechanisms associated with the co-methylated genes that are correlated to the phenotypic traits of obesity, we also performed a functional enrichment analysis of genes with DMRs in promoters using DAVID software [@B20] (Table [1](#T1){ref-type="table"}).

SATs are associated with metabolic processes
--------------------------------------------

As shown in Fig. [2](#F2){ref-type="fig"}, the co-methylated genes in SATs modulate three metabolic indicators in serum, specifically Apo-A1, HDL and LDL. These indicators are primarily involved in metabolic processes, such as cellular carbohydrate biosynthesis, cholesterol, glycerolipid, and lipopolysaccharide metabolism, and biosynthesis of cellular carbohydrates, polysaccharides, and macromolecules (Table [1](#T1){ref-type="table"}).

This finding corroborated the notion that SATs, which are distributed over the body\'s surface in the hypodermal layer of the skin, mainly contribute to metabolism, and have direct and beneficial effects on the maintenance of body weight and metabolism [@B5]-[@B7]. It is noteworthy that, in most regions of the human and pig bodies, SAT is anatomically separated by a stromal fascia into superficial and deep SATs [@B21]. Walker *et al.* (2007) reported that compared to human superficial SAT, deep SAT appears to be a distinct adipose depot that supports an independent metabolic function and may be associated with the risk of obesity-associated complications [@B22]. Nonetheless, similar to the upper layer of porcine backfat (i.e. ULB), the co-methylated genes in the inner layer of porcine backfat (i.e. ILB) were related to two metabolic indicators (i.e. Apo-A1 and HDL), and were also mainly enriched in metabolic-related Gene Ontology (GO) terms (Fig. [2](#F2){ref-type="fig"}). Currently, little is known about the species-specific differences in the distribution of adipose tissues, and future comprehensive comparisons of physiological and biochemical characteristics between humans and pig will be beneficial in ascertaining this discrepancy in the results.

VATs are attributed to inflammatory and immune processes
--------------------------------------------------------

As shown in the Fig. [2](#F2){ref-type="fig"}, apart from RAD, co-methylated genes in the other three VATs (i.e. GOM, PAD and MAD) were found to primarily affect three inflammatory and immune adipokines in serum: IL-6, PAI-1 and TNF-*α*. These adipokines are markedly involved in the differentiation of B-cells, T-cells, leukocytes, and lymphocytes, and in the development of the immune system, and hemopoietic and lymphoid organs. Consequently, these adipokines further attribute to the obesity-induced chronic inflammation in adipose tissue that precedes the development of insulin resistance and type II diabetes mellitus [@B23]-[@B25].

It is believed that the distribution of adipose is an important predictor of metabolic abnormalities, rather than total adipose mass [@B3], [@B4]. VATs are located within the abdominal cavity (i.e. GOM and MAD), and have been recognized to be anatomically, functionally, and metabolically distinct from SATs [@B3], [@B26]. Differences between VATs and SATs arise from the different genetic differentiation of pre-adipocytes and the influence of the local microenvironment [@B26]. The venous drainage of abdominal VATs is via the portal system, which directly provides free fatty acids (FFAs) as substrates for hepatic lipoprotein metabolism and glucose production [@B27]. Compared with SATs, VATs are more cellular, vascular, innervated, and contain a larger number of inflammatory and immune cells [@B25]. VAT adipocytes are more metabolically active and have a greater capacity to generate FFAs and uptake glucose than SATs, while SATs are more avid in absorbing circulating FFAs and triglycerides [@B2]. A recent study on the autologous transplantation of VATs to subcutaneous sites suggested that the DNA methylation status of the promoters of adipokine genes across different adipose depots are anatomic location-specific, and are influenced by the impact of local (residence) factors [@B5]. With the exception of GOM and MAD, we did not identify gene sets of RAD that are significantly associated with a phenotypic trait of obesity. This may be attributed to its special anatomical location, which surrounds the kidneys at the dorsal side of the abdominal cavity. Blood from omental GOM and mesenteric MAD drains into the portal vein, while blood from retroperitoneal RAD does not.

Interestingly, we also found that the co-methylated genes of PAD, which is located within the thoracic cavity and surrounds the heart, primarily affect inflammatory and immune adipokines (i.e. IL-6, PAI-1 and TNF-*α*) (Fig. [2](#F2){ref-type="fig"}). This observation confirms the evidence that PAD is a correlative risk factor for cardiovascular disease [@B28], especially coronary heart disease owing to the marked feature of inflammation [@B29]. Additionally, similar to high-risk VATs, the co-methylated genes of intermuscular IAD, which is believed to provide fuel for skeletal muscle contraction, were found to affect IL-6, PAI-1 and TNF-α (Fig. [2](#F2){ref-type="fig"}), suggesting that it is an independent risk factor for metabolic diseases [@B30].

Conclusion
==========

The present study found that intrinsic methylation differences between various adipose depots are dependent on their localization. Additionally, we presented epigenetic evidence that both VATs and IAD, which are metabolic risk factors of obesity, are also associated with an impaired immune response. Our observations suggest a potential strategy for the development of future epigenetic biomarkers for the prediction and prevention of obesity.
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![**Heat map of co-methylated gene sets in eight adipose tissues.** Three SATs (abdominal subcutaneous adipose (ASA), inner layer of backfat (ILB), upper layer of backfat (ULB)); four VATs (greater omentum (GOM), mesenteric adipose (MAD), retroperitoneal adipose (RAD), pericardial adipose (PAD)); and intermuscular adipose (IAD). Pair-wise correlations between genes residing in all the gene sets were plotted. Gene pairs strongly positively or negatively correlated are shown in red or green, respectively. Colour intensity represents the strength of the correlation. The co-methylated gene sets are indicated by squares and are ordered by the number of genes; thus with the largest gene set - containing the largest number of genes - in the upper left corner and the smallest gene set in the lower right corner.](ijbsv08p0831g01){#F1}

![**Correlations between co-methylated gene sets in eight adipose tissues and phenotypic traits of obesity.**Log~10~ *P*-values for Spearman rank correlation coefficients between the methylation values of the gene sets and the different phenotypic traits of obesity are shown. The gray shadow represents the Bonferroni corrected *P*-values that are greater than 0.001. SFA, MUFA, and PUFA, denote saturated, monounsaturated, and polyunsaturated fatty acids, respectively.](ijbsv08p0831g02){#F2}

###### 

Top ten Gene Ontology (GO) and KEGG pathway categories enriched for co-methylated gene sets that correlated with phenotypic traits of obesity.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Correlated trait                      Tissue (gene sets order No.)                                 Functional category   Term description                                               *P* value   Involved gene No.
  ------------------------------------- ------------------------------------------------------------ --------------------- -------------------------------------------------------------- ----------- -------------------
  Apo-A1\                               ASA (2)\                                                     GO-BP                 Cellular carbohydrate biosynthetic process                     0.002       12
  (Metabolic indicator)                 ILB (3)                                                                                                                                                       

  GO-BP                                 Regulation of small GTPase mediated signal transduction      0.003                 27                                                                         

  GO-BP                                 Positive regulation of growth                                0.006                 11                                                                         

  GO-BP                                 Carbohydrate biosynthetic process                            0.008                 14                                                                         

  GO-MF                                 GTPase regulator activity                                    0.009                 35                                                                         

  GO-MF                                 Small GTPase regulator activity                              0.009                 27                                                                         

  GO-BP                                 Glycerolipid metabolic process                               0.021                 20                                                                         

  GO-BP                                 Positive regulation of cell proliferation                    0.025                 34                                                                         

  GO-BP                                 Cholesterol metabolic process                                0.029                 13                                                                         

  GO-BP                                 Response to steroid hormone stimulus                         0.040                 18                                                                         

  HDL\                                  ILB (5)\                                                     GO-MF                 SH2 domain binding                                             0.003       17
  (Metabolic indicator)                 ULB (1)                                                                                                                                                       

  GO-MF                                 Manganese ion binding                                        0.008                 25                                                                         

  GO-BP                                 Gastrulation                                                 0.009                 20                                                                         

  GO-BP                                 Regulation of response to external stimulus                  0.009                 26                                                                         

  GO-MF                                 Enzyme activator activity                                    0.013                 34                                                                         

  GO-BP                                 Regulation of growth                                         0.015                 34                                                                         

  GO-BP                                 Regulation of smoothened signaling pathway                   0.016                 16                                                                         

  GO-BP                                 Positive regulation of anti-apoptosis                        0.018                 17                                                                         

  GO-BP                                 Striated muscle tissue development                           0.032                 22                                                                         

  GO-BP                                 Cell projection assembly                                     0.032                 20                                                                         

  LDL\                                  ASA (1)\                                                     GO-BP                 Cellular carbohydrate biosynthetic process                     0.001       12
  (Metabolic indicator)                 ULB (2,4)                                                                                                                                                     

  GO-BP                                 Purine ribonucleoside triphosphate biosynthetic process      0.002                 15                                                                         

  GO-BP                                 Cellular polysaccharide biosynthetic process                 0.002                 8                                                                          

  GO-BP                                 Positive regulation of biosynthetic process                  0.003                 72                                                                         

  GO-BP                                 ATP biosynthetic process                                     0.003                 14                                                                         

  GO-BP                                 Ribonucleoside triphosphate biosynthetic process             0.003                 15                                                                         

  GO-BP                                 Positive regulation of macromolecule biosynthetic process    0.005                 67                                                                         

  GO-BP                                 Polysaccharide biosynthetic process                          0.005                 10                                                                         

  GO-MF                                 Transferase activity, transferring nitrogenous groups        0.005                 8                                                                          

  GO-BP                                 Lipopolysaccharide metabolic process                         0.007                 4                                                                          

  IL-6\                                 GOM (1,3)\                                                   GO-BP                 Regulation of cell morphogenesis involved in differentiation   0.001       18
  (Inflammatory and immune adipokine)   PAD (3)\                                                                                                                                                      
                                        IAD (4)                                                                                                                                                       

  GO-BP                                 Response to hypoxia                                          0.005                 25                                                                         

  GO-BP                                 Gliogenesis                                                  0.011                 16                                                                         

  GO-BP                                 Immune response-activating cell surface receptor signaling   0.013                 13                                                                         

  GO-MF                                 Steroid hormone receptor binding                             0.013                 13                                                                         

  GO-BP                                 Regulation of cell morphogenesis                             0.023                 22                                                                         

  GO-BP                                 Positive regulation of leukocyte chemotaxis                  0.023                 9                                                                          

  GO-BP                                 Immune response-regulating cell surface receptor signaling   0.023                 13                                                                         

  GO-BP                                 Regulation of cAMP metabolic process                         0.031                 19                                                                         

  GO-BP                                 Regulation of leukocyte chemotaxis                           0.033                 9                                                                          

  TNF-*α*\                              MAD (1)\                                                     GO-BP                 Leukocyte differentiation                                      0.003       16
  (Inflammatory and immune adipokine)   PAD (3)\                                                                                                                                                      
                                        IAD (4)                                                                                                                                                       

  GO-BP                                 B cell activation                                            0.004                 13                                                                         

  GO-BP                                 Cellular component morphogenesis                             0.005                 28                                                                         

  GO-BP                                 Lymphocyte differentiation                                   0.008                 15                                                                         

  GO-BP                                 B cell differentiation                                       0.012                 11                                                                         

  GO-MF                                 Small GTPase regulator activity                              0.014                 22                                                                         

  GO-BP                                 Hemopoietic or lymphoid organ development                    0.020                 21                                                                         

  KEGG                                  Primary immunodeficiency pathway                             0.020                 10                                                                         

  GO-BP                                 Regulation of T cell activation                              0.034                 14                                                                         

  GO-BP                                 Immune system development                                    0.036                 21                                                                         

  PAI-1\                                MAD (1,3)\                                                   GO-BP                 Leukocyte differentiation                                      0.004       18
  (Inflammatory and immune adipokine)   PAD (3)\                                                                                                                                                      
                                        IAD (4)                                                                                                                                                       

  GO-MF                                 Magnesium ion binding                                        0.005                 38                                                                         

  GO-BP                                 Lymphocyte differentiation                                   0.006                 17                                                                         

  KEGG                                  Primary immunodeficiency pathway                             0.007                 11                                                                         

  GO-BP                                 Hemopoiesis                                                  0.009                 25                                                                         

  GO-BP                                 B cell activation                                            0.009                 14                                                                         

  GO-BP                                 Hemopoietic or lymphoid organ development                    0.013                 25                                                                         

  GO-BP                                 T cell differentiation                                       0.015                 13                                                                         

  GO-BP                                 T cell differentiation in the thymus                         0.020                 10                                                                         

  GO-BP                                 Immune system development                                    0.029                 25                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In all tests, the unified set of co-methylated genes for different adipose depots that correlated to a phenotypic trait of obesity were compared with all known genes, which served as the background. *P* values (i.e. corrected EASE score), which indicated the significance of the overlap between various gene sets, was calculated using Benjamini-corrected modified Fisher\'s exact test. BP, biological process; MF, molecular function.
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